Companies
Every startup building in Florida. Click a row for details.
Adze BiotechnologyAdze Biotechnology is a pre-clinical stage company that develops oncolytic immunotherapies for the treatment of cancers. It has exclusive licenses to oncolytic immunotherapies developed in the lab of Dr. Michael Barry of Mayo Clinic. The company was founded in 2019 and is based in Coral Gables, Florida. | Biotechnology | MIA | 2019 | $6.2M |
AmbuleroAmbulero, Inc is a cell and gene therapy spin-out of the University of Miami focused on advancing new therapies to fight vascular disease. | Biotechnology | MIA | 2019 | $5.5M |
Ascend Advanced TherapiesAscend helps make and sell gene therapy treatments. We know a lot about how to create and share these special medicines. | Biotechnology | GNV | 2022 | $131M |
ASP IsotopesASP Isotopes is a pre-commercial stage advanced materials company that develops isotope enrichment technology for the medical, green energy, and industrial sectors | Biotechnology | MIA | 2021 | $372M |
Beacon TherapeuticsBeacon Therapeutics is a biotechnology firm in the clinical stage focused on preserving and enhancing vision for individuals affected by both uncommon and widespread eye disorders. The organization is leveraging the revolutionary potential of gene therapy to achieve significant results for serious eye conditions. Currently, Beacon's pipeline is aimed at severe retinal diseases that cause blindness, including X-linked retinitis pigmentosa (XLRP) and geographic atrophy. | Biotechnology | GNV | 2023 | $365M |
BetaliqBetaliq is a collaboration between Novaliq, GMBH, and BLP Management Group, LLC. It was formed to develop ophthalmic beta-blockers using Novaliq’s patented EyeSol non-water formulation technology. The company is developing two beta-blockers, for the treatment of glaucoma. BTQ 1901 is an EyeSol based formulation of a potent selective beta-blocker that has not previously been used to treat glaucoma. BTQ 1902 is an EyeSol based formulation of timolol, the most commonly prescribed beta-blockers. | Biotechnology | TPA | 2018 | $6.0M |
CellVax Therapeutics Inc.CellVax Therapeutics is a privately-held clinical-stage company developing autologous anticancer vaccines | Biotechnology | MIA | 2020 | $7.3M |
Continuity BiosciencesContinuity Biosciences is a biotech business. The business is focused on developing and commercializing innovative drug delivery technologies, with a special emphasis on cell reprogramming, immune regulation, and ultra-long-acting delivery systems. | Biotechnology | SWFL | 2023 | $12M |
Disruption LabsDisruption Labs core strategy is a B2B business model, working in partnership with multi-national corporations and high-growth SMEs in the functional food & beverage and clinical therapeutic markets to improve or bio-enhance existing products areas, or create entirely new disruptive products. Disruption Labs performs R&D, including pharmacokinetic studies, to demonstrate product safety and improved efficacy, facilitating new product development from the lab bench top to product scale-up through market - offering a true end-to-end solution. In instance in which these strategic partnerships are not available, Disruption Labs plans to launch its own niche branded products, with R&D performed in-house to develop, scale-up and tech transfer, to bring to market scientifically validated, cutting-edge bio-enhanced product lines employing the proven, proprietary nanotechnology platform. Currently, Disruption Labs has developed a nano-liposomal CBD water soluble formulation, which utilizes its proprietary proven nanotechnology platform. The product is now sold under the brand Reset Bioscience, is currently being scientifically tested and validated for pharmacokinetic properties and manufactured under GMP-compliant conditions. Reset Biosciences has launched its first bio-enhanced, pharmaceutical grade, nano-liposomal product RESET Balance Jan 2019. More on RESET RESET Bioscience, a CBD and advanced wellness company, is the first to use pharmaceutical grade ingredients, and processes, for its pioneering CBD product. After extensive research, testing and validation the company is launching its debut product - RESET Balance, a 99.9% nano liposomal organic hemp CBD that compliments the body’s existing endocannabinoid system. The type of advanced nanotechnology used to produce this product uses liposomes as the trojan horse of drug delivery, providing approximately a 80% absorption/CBD effect at the cellular level, the highest in the industry today. With a commitment to quality, RESET Bioscience has spent $2M to double test for purity and efficacy, to introduce a product that will work as hard as you do to “reset” you to your baseline managing everyday stressors, including pain, anxiety, insomnia and more. RESET Balance is available in two flavors, neutral and peppermint, and is power packed with 300mg of organic triple tested CBD isolate, the most researched form of CBD on the market today, and importantly, with 0% THC. A unique attribute to RESET Balance is that it is white in color, due to the purity of the pharmaceutical grade lipids used. RESET has committed to self-regulate its developmental process, which means more safety and quality control measures have been taken to test and deliver a product that achieves real results, setting a new standard for CBD bioavailability through its proprietary nano liposomal delivery system. | Biotechnology | TPA | 2017 | $3.8M |
Empowered DiagnosticsEmpowered Diagnostics delivers innovative diagnostic tests backed by experts in healthcare and biotechnology. The company is driven by a mission to empower people with the knowledge and confidence to understand their health through reliable, affordable, high-quality tests. | Biotechnology | MIA | 2017 | $4.7M |
Gibson OncologyGibson Oncology acquired the Indenos to provide a noticeable positive impact on cancer patient’s lives in two critical areas. First, cancer resistance continues to emerge among almost all cancer patients whom initially responded to some form of treatment. Indenos were specifically designed to achieve high drug concentrations and remain within cancer cells for optimal anti-cancer activity, which reduces the chances that cancer cells’ can remove the anti-cancer drug to avoid its own destruction – thus, Indenos fight cancer resistance. Second, Indenos have a favorable side effect profile so that cancer patients experience a better quality of life during treatment with no grade 3 or 4 diarrhea and much less grade 3 and 4 neutropenia. They believe, therefore, that their goal of Being Tough on Cancer, not on Patients, can be achieved through these novel anti-cancer drugs, and their planned Phase II trials are well-positioned for treating resistant cancers in children and adults. | Biotechnology | MIA | 2018 | $4.0M |
Gradian DiagnosticsGradian Diagnostics is a biotechnology company that focuses on developing Next-Gen medical and diagnostics technologies. Its philosophy is to take a practical approach to develop its portfolio. The company believes that inspiration must always be backed up by a heavy dose of quantitative evidence and apply hard-nosed management fundamentals to ensure science actually turns into commercially successful products that make a the difference in the lives of patients. The company was founded in 2018 and is headquartered in Miami Beach, Florida. | Biotechnology | MIA | 2018 | $3.1M |
HCW BiologicsHCW Biologics is developing immunotherapies to lengthen healthspan by disrupting the link between cellular senescence and disease. | Biotechnology | PAN | 2018 | $89M |
ImaginosticsImaginostics is a health tech company developing a quantitative vascular MRI platform (ImagiView™) and AI-powered biomarker engine (ImagiSight™) that transforms standard MRI scanners into precision diagnostic instruments — no new hardware required. From a single scan on existing MRI systems, the platform generates individual-patient maps of microvascular density, blood-brain barrier permeability, and vessel structure. Lead indications include malignant brain neoplasm and Alzheimer's disease. Imaginostics holds FDA Breakthrough Device Designation and a letter of support from Siemens Healthineers, and is backed by the NIH and the Alzheimer's Drug Discovery Foundation. | Biotechnology | ORL | 2018 | $8.5M |
ImmunoProfileImmunoProfile is a biotechnology company that focuses on manufacturing diagnostic kits for multiple therapeutic areas. | Biotechnology | SWFL | 2018 | $3.0M |
Inflammx TherapeuticsInflammx Therapeutics is a biotechnology startup company. It was founded in Tampa, Florida in 2020. | Biotechnology | TPA | 2020 | $14M |
Innovative GeneticsInnovative Genetics is building the infrastructure layer behind the next wave of compliant therapeutics. We develop and license BioIP—fast-acting formulations, nationally trademarked brand systems, compliant packaging, and deployable production infrastructure—designed for scale, structured for recurring revenue, and protected by intellectual property. Our model is entirely non-substance-touching, enabling operators in legal U.S. markets to commercialize without federal exposure or capital-heavy overhead. We generate revenue through licensing, royalties, and infrastructure leasing—without cultivation, manufacturing, or retail. | Biotechnology | MIA | 2017 | $6.0M |
Ki HealthKihealth is poised to revolutionize diabetes care with the launch of the world's first blood test capable of identifying diabetes risk before symptoms emerge. This innovative point-of-care and at-home diagnostic test developed at Yale University is set to become the new standard of care in adolescent screening and emerge as a crucial instrument in early detection for type 2 diabetes. | Biotechnology | JAX | 2023 | $5.0M |
Lacerta TherapeuticsLacerta Therapeutics is a clinical stage gene therapy company using a constellation of proprietary adeno-associated virus (AAV) vector technologies to develop treatments for central nervous system and lysosomal storage diseases. With unmatched scientific expertise and depth in the development, production, and application of AAV vectors, Lacerta Therapeutics is advancing its clinical programs using its proprietary capsid variants and scalable vector manufacturing platform. The experience and accomplishments of the Lacerta Therapeutics founders are unsurpassed in AAV gene therapy. In addition to world-class basic AAV vector development and gene therapy clinical trial expertise, our team brings to bear individuals with novel insight into developing novel, targeted neurological and lysosomal storage disease treatments. | Biotechnology | GNV | 2017 | $30M |
MarizymeMarizyme is a development-stage company dedicated to the commercialization of therapies that address the urgent need for higher mortality and costs in the acute care space. The company's first product candidates are derived from a broad intellectual property portfolio around a novel system of proteolytic enzymes called ProteomeX (previously referred to as Krillase Technology). Marizyme completed the acquisition of these assets and intends to immediately develop several product candidates that will address unmet medical needs in the acute care setting. | Biotechnology | MIA | 2018 | $5.6M |
1–20 of 32 results